Bayer's Asundexian Achieves Key Efficacy and Safety Goals in Phase III Trial

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Nov 23 2025

0mins

Positive Study Results: Bayer's Phase III study OCEANIC-STROKE showed that the oral FXIa inhibitor asundexian significantly reduced the risk of ischemic stroke compared to placebo.
Safety Profile: The study found no increase in the risk of major bleeding in patients treated with asundexian alongside antiplatelet therapy.
Dosage and Administration: Asundexian was administered at a dosage of 50 mg once daily in the study.
Future Presentations: Detailed results from the OCEANIC-STROKE study are set to be presented at an upcoming scientific congress.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.